BioMedInvest AG I, LSP Life Sciences Partners and TVM Capital closed a CHF 17m series-A round for Vivendy Therapeutics Ltd., a bio-pharmaceutical company located in Basel, Switzerland. Vivendy is a pharmaceutical start-up company that is developing an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis (MPS) IVA), a rare lysosomal storage disease. It was founded in 2006 as a spin-off from Inotech Biotechnologies AG.
EMZ recently opened its first international office in Munich, headed by partner Klaus Maurer
Fund deploys tickets of €1-5m in seed and series-A rounds to support European B2B SaaS startups
French GP is planning to take exclusive control of the fire safety specialist
Insight, Deutsche Telekom Capital Partners, Capnamic and Iris Capital also participate